小牛脾提取物注射液联合XELOX化疗方案治疗晚期胃癌患者的效果  

Effects of calf spleen extractive injection combined with XELOX chemotherapy regimen in treatment of patients with advanced gastric cancer

作　　者：傅育豪 陈瑞德[2] FU Yuhao;CHEN Ruide(Oncology of Puning Overseas Chinese Hospital,Department of Oncology,Puning 515300 Guangdong,China;Oncology of Puning Overseas Chinese Hospital,Department of Ophthalmology,Puning 515300 Guangdong,China)

机构地区：[1]普宁华侨医院肿瘤内科,广东普宁515300 [2]普宁华侨医院眼科,广东普宁515300

出　　处：《中国民康医学》2021年第21期18-20,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察小牛脾提取物注射液联合XELOX(奥沙利铂+卡培他滨)化疗方案治疗晚期胃癌患者的效果。方法:选取68例晚期胃癌患者为研究对象,采用随机数字表法分为对照组和观察组各34例。对照组采用XELOX化疗方案治疗,观察组在对照组基础上联合小牛脾提取物注射液治疗,比较两组临床疗效[客观缓解率(ORR)、疾病控制率(DCR)]、治疗前后T细胞亚群指标[CD3^(+)、CD4^(+)、CD8^(+)]水平、不良反应发生率和1年生存率。结果:治疗后,观察组ORR、DCR分别为67.65%、94.12%,分别高于对照组的41.18%、70.59%,差异均有统计学意义(P<0.05);观察组CD3^(+)、CD4^(+)水平均高于治疗前,对照组低于治疗前,但观察组高于对照组,差异有统计学意义(P<0.05);观察组CD8^(+)水平低于治疗前,对照组高于治疗前,但观察组低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组1年生存率为94.12%,高于对照组的76.47%,差异有统计学意义(P<0.05)。结论:小牛脾提取物注射液联合XELOX化疗方案治疗晚期胃癌患者可提高ORR、DCR和1年生存率,以及改善T细胞亚群指标水平,效果优于单纯XELOX化疗方案治疗。Objective:To observe effects of calf spleen extractive injection combined with XELOX chemotherapy regimen(Oxaliplatin+Capecitabine)in treatment of patients with advanced gastric cancer.Methods:68 patients with advanced gastric cancer were selected as the research objects,and were divided into control group and observation group by using the random number table method,34 cases in each group.The control group was treated with XELOX chemotherapy,while the observation group was treated with calf spleen extract injection on the basis of that of the control group.The clinical efficacy[objective remission rate(ORR),disease control rate(DCR)],the T cell subgroup indexes[CD3^(+),CD4^(+),CD8^(+)]levels before and after the treatment,the incidence of adverse reactions and the 1-year survival rate were compared between the two groups.Results:After the treatment,the ORR and DCR of the observation group were 67.65%and 94.12%,respectively,which were higher than 41.18%and 70.59%of the control group,and he differences were statistically significant(P<0.05).The CD3^(+) and CD4^(+) levels in the observation group were higher than those before the treatment;the CD3^(+) and CD4^(+) levels in the control group were lower than those before the treatment;those of the observation group were higher than those of the control group;and the differences were statistically significant(P<0.05).The CD8^(+) level of the observation group was lower than that before the treatment;the CD8^(+) level of the control group was higher than that before the treatment;that of the observation group was lower than that of the control group;and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).The 1-year survival rate of the observation group was 94.12%,which was higher than the 76.47%of the control group,and the difference was statistically significant(P<0.05).Conclusions:Calf spleen extractive injection combined with XELOX chemotherapy

关 键 词：胃癌 晚期 小牛脾提取物注射液 XELOX化疗方案 

分 类 号：R735.2[医药卫生—肿瘤]